PI Industries Limited
Pesticides
& Agrochemicals
Annual Returns


Cumulative Returns and Drawdowns


Ownership

Margined

AI Summary
asof: 2026-09-16
PI Industries (PIIND) — 79th AGM Voting Analysis
1. Headwinds and Challenges
- Director re-appointment drew significant institutional
dissent. Resolution 3, the re-appointment of Mr. Rafael Del Rio
Donoso as a director retiring by rotation, passed but with 12,425,320
votes against — 9.06% of votes polled. Public institutions opposed it
heavily: 12,423,965 votes against, or 18.74% of their votes polled.
- Remuneration for Mr. Rafael Del Rio Donoso faced the
strongest opposition. Resolution 6, covering remuneration
payable to him as a Non-Executive Non-Independent Director, saw
21,443,079 votes against — 15.63% of votes polled. Public institutions
cast 21,441,695 votes against, representing 32.32% of their votes
polled.
- Independent director re-appointments also attracted notable
negative votes. Resolution 9 (re-appointment of Ms. Pia Singh)
recorded 13,077,512 votes against, or 9.53% of votes polled, with public
institutions opposing at 19.71% of their votes. Resolution 8
(re-appointment of Mr. Shobinder Duggal) saw 725,858 votes against, or
0.53% of votes polled, with 1.11% of public institutional votes
against.
- The special resolution for Dr. Atul Kumar Gupta’s
appointment as Whole Time Director was not unanimous.
Resolution 7 passed with 1,346,215 votes against, or 0.98% of votes
polled; public institutions opposed at 2.03% of their votes.
- Even routine resolutions saw minor dissent.
Resolution 2 (dividend confirmation/declaration) had 36,103 votes
against, and Resolution 5 (cost auditor remuneration ratification) had
1,086 votes against.
2. Tailwinds and Growth Prospects
- All nine resolutions were passed with the requisite
majority, as confirmed by the Scrutinizer’s Report dated August
14, 2026, issued by Mr. Ashish Kumar Friends, Practicing Company
Secretary, A.K Friends and Company.
- Strong shareholder participation. Total votes
polled across resolutions ranged from 89.86% to 90.41% of outstanding
shares, indicating broad engagement.
- Promoter and promoter group support was unanimous.
On every resolution, 69,920,474 promoter votes were polled, all in
favour, with zero against.
- Dividend resolutions received near-total backing.
Resolution 2, confirming an interim dividend of Rs. 5.00 per equity
share and declaring a final dividend of Rs. 10.00 per equity share (face
value Re. 1.00 each), passed with 99.97% of votes in favour.
- Board continuity and leadership appointments were
endorsed. Mr. Rafael Del Rio Donoso was re-appointed
(Resolution 3), Dr. Atul Kumar Gupta was appointed as Director and Whole
Time Director (Resolution 7), and Mr. Shobinder Duggal (Resolution 8)
and Ms. Pia Singh (Resolution 9) were re-appointed as Independent
Directors.
- Governance housekeeping was completed. Resolution 4
approved non-filling of the vacancy caused by retirement of Mr. Arvind
Singhal as Non-Executive Non-Independent Director, and Resolution 5
ratified cost auditor remuneration for FY 2026-27.
3. Key Risks
- Concentration of promoter voting power. Promoter
and promoter group held 69,920,474 shares, and their 100% in-favour
votes were decisive in passing all resolutions, including those where
public institutional opposition was material.
- Institutional investor dissatisfaction. The high
against-votes from public institutions on Resolutions 3, 6, 8, and 9
signal governance or remuneration-related concerns among institutional
shareholders.
- Related-party/remuneration sensitivity. The
remuneration resolution for Mr. Rafael Del Rio Donoso (Resolution 6)
attracted the largest protest vote (15.63% overall, 32.32% of public
institutional votes), indicating sensitivity around non-executive
director compensation.
- Board composition changes. The retirement of
Mr. Arvind Singhal and the decision not to fill the vacancy (Resolution
4) alters board composition.
Broker Narrative
The narrative moved from an overwhelmingly Buy/Accumulate stance in
2023-24, built on CSM growth, a patented-molecule moat and pharma
diversification, to a defensive Hold by August 2026 as CSM/agchem and
pharma revenues contracted. Weather/monsoon risk, input-cost margin
pressure and generic-market stress persisted as recurring concerns from
the first report to the last. The key change was the erosion of the
‘patented/innovator moat’ thesis: pyroxasulfone off-patent and
genericization replaced pipeline optimism as the central challenge.
Fears that came true
- The weather/monsoon risk materialized, with later reports citing
heat waves, delayed sowing and high inventory hurting domestic core
agchem.
- Input-cost pressure materialized, as domestic agri margins remained
under pressure due to higher input costs.
- Generic-market stress materialized, with global agrochemical
genericization and pyroxasulfone going off patent hurting CSM
growth.
- Export/CSM weakness materialized, as CSM segment revenue fell 12.7%
YoY due to soft commodity prices and genericization.
Optimism that failed
- The strong CSM growth/pipeline optimism failed: projected 20% CSM
CAGR and a ~USD 1.8bn order book did not prevent a 12.7% YoY CSM revenue
decline.
- Pharma diversification optimism failed: expected pharma revenue
contribution did not provide stability, as pharma revenue contracted 25%
YoY due to order book phasing.
- The patented/innovator-moat optimism failed: the portfolio was not
immune to generic headwinds, with pyroxasulfone off-patent concentration
becoming a growth challenge.
- The domestic traction/guidance optimism failed: the 18-20% FY24
ex-pharma revenue growth view was undermined by heat waves, delayed
sowing and high inventory, with later branded agchem growth only 2%
YoY.
Broker Timeline
24 broker calls · 2023-05-22 to 2026-08-12
CNBC-TV18: ratings, targets and commentary
No recorded CNBC-TV18 statements for this ticker.
Management comments
No recorded management comments with an explicit designation and affiliation for this ticker.
Copyright © 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.
🐞